Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Most evidence for anticoagulation in aortic bioprosthesis is centered on embolic events, bleeding and re-intervention risk. The effect of anticoagulation on hemodynamics has not been previously assessed. Our hypothesis was that patients with anticoagulation (AC) early after aortic valve replacement (AVR) with porcine bioprosthesis have better hemodynamics at 3 years of follow-up.
Methods: This is a follow-up evaluation of the ANTIPRO trial. All patients undergoing AVR with porcine bioprosthesis were consecutively recruited. The AC group received warfarin+aspirin and the non-AC(control) only aspirin. The primary outcome was mean gradient after 3 years of AVR and change in New York Heart Association (NYHA) class. Secondary outcomes were major and minor bleeding and embolic events.
Results: Of 140 participants in the study, 71 were assigned to the AC group and 69 to the control group. Mean age of the overall population was 72.4(SD: 7.1) years. Global euroSCORE was 7.65(SD: 5.73). At 3 years the mean gradient was similar between both groups (19.4(SD: 9.6 mmHg) and 18.6(SD: 8.2 mmHg) in the control and AC group respectively, p = 0.7). No differences in functional class at 3 years were found among groups. No differences were found among groups in the secondary outcomes.
Conclusions: The addition of 3 months of oral anticoagulation to anti-aggregation treatment did not affect bioprosthetic hemodynamics nor functional class at years after AVR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2024.132361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bioprosthetic valve replacement for concomitant aortic and mitral positions.
JTCVS Open
August 2025
Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Objective: To compare the clinical outcomes of double-valve replacement (DVR) using bovine pericardial and porcine bioprostheses, using a nationwide administrative claims database.
Methods: Adult patients (age ≥40 years) who underwent bioprosthetic DVR between 2003 and 2018 were identified from the Korean National Health Insurance Service database. The outcomes of interest were all-cause mortality, cardiac mortality, and valve-related events, including the incidences of reoperation, endocarditis, systemic thromboembolism, and major bleeding.
Engineering of bioprosthetic heart valves with synergistic zwitterionic surface modification and zirconium cross-linking for improved biocompatibility and durability.
Acta Biomater
July 2025
National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610065, China.
Bioprosthetic heart valves (BHVs) are frequently utilized in surgeries for heart valve replacement to address valvular heart disease (VHD). Despite their widespread use, BHVs still face challenges in clinical applications, such as thrombosis, calcification, immune responses, poor re-endothelialization, infection, component degradation, and mechanical failure, which are largely due to the heterogeneous cross-linking effects. To address these issues, we propose a synergistic engineering strategy based on sequential zwitterionic surface modification and zirconium cross-linking to improve the biocompatibility and durability of BHVs.
View Article and Find Full Text PDFLong-term outcomes of pulmonary valve replacement in adolescents and adults: A nationwide population-based study.
Int J Cardiol
October 2025
Division of Clinical Epidemiology, Medical Research Collaborating Center, Biomedical Research Institution, Seoul National University Hospital, Seoul, Republic of Korea.
Objective: A study using the National Health Insurance Service database compared bioprosthetic and mechanical pulmonary valve replacement clinical results.
Methods: Total of 1586 patients underwent pulmonary valve replacement from 2003 to 2021 and 1295 patients were enrolled after excluding those with previous aortic valve replacement and aged less than 13 years at operation. Bioprostheses (group B) and mechanical prostheses (group M) were used in 1085 patients (83.
In Vitro Evaluation of Biomaterials for Heart Valve Prosthesis: High Hydrostatic and Enzymatic Treatments as Alternative for Bio-Derived Materials.
J Biomed Mater Res B Appl Biomater
June 2025
Ri.MED Foundation, Palermo, Italy.
Various biomaterials are currently used in clinical settings for heart valve repair and replacement. However, the optimal tissue preparation technique remains elusive. In this study, a non-crosslinked tissue obtained from bovine pericardium, developed by Adeka Corporation, was compared with three commercially-available tissues: two fixed tissues obtained from crosslinked bovine pericardium, CryoLife PhotoFix and LeMaitre CardioCel, and an unfixed one obtained from swine intestinal submucosa, CorMatrix CorPatch.
View Article and Find Full Text PDFA Novel Aldehyde Scavenging Modification Boosted Pericardium Valve Materials against Calcification.
Adv Healthc Mater
July 2025
Institute for Smart Biomedical Materials, School of Materials Science & Engineering, Zhejiang Sci-Tech University, Hangzhou, Zhejiang, 310018, China.
Calcific aortic valve disease is an inexorably degenerative pathology and a common cause of morbidity and mortality in heart disease. Clinically, it has no effective medical therapy but can be managed with artificial heart valve replacement, particularly using bioprosthetic heart valves (BHV), entailing high biocompatibility. Current BHV mainly derives from glutaraldehyde (GA) cross-linked pericardium, however, residual aldehyde groups may inevitably remain during cross-link, potentially binding with calcium and inducing in situ calcification after implantation, thus leading to valve re-failure and posing a significant clinical challenge.
View Article and Find Full Text PDF